The full edition of the report is available at Xinhua Silk Road Database. You can click the “Table of Content” to have a general understanding of it.
Click on the button below to create your account and get immediate access to thousands of articles.
China's self-developed cancer drug approved in 50 markets
Chinese biotechnology company BeiGene announced on Monday that its self-developed cancer drug, known as Brukinsa (zanubrutinib) in capsule form, was approved in Kuwait, Bahrain and Qatar for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, reported China Securities Journal.
June14,2022
If you have any questions, please enter them in the box below.
Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to silkroadweekly@xinhua.org and share your stories with more people.
Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.
